PE20070806A1 - Composicion farmaceutica que comprende un derivado de diarilurea - Google Patents

Composicion farmaceutica que comprende un derivado de diarilurea

Info

Publication number
PE20070806A1
PE20070806A1 PE2006001406A PE2006001406A PE20070806A1 PE 20070806 A1 PE20070806 A1 PE 20070806A1 PE 2006001406 A PE2006001406 A PE 2006001406A PE 2006001406 A PE2006001406 A PE 2006001406A PE 20070806 A1 PE20070806 A1 PE 20070806A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
composition including
composition
diarylurea
diarylurea derivative
Prior art date
Application number
PE2006001406A
Other languages
English (en)
Spanish (es)
Inventor
Peter Sandner
Hanna Tinel
Joachim Hutter
Bernd Riedl
Martina Klein
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20070806A1 publication Critical patent/PE20070806A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2006001406A 2005-11-10 2006-11-09 Composicion farmaceutica que comprende un derivado de diarilurea PE20070806A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
PE20070806A1 true PE20070806A1 (es) 2007-09-29

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001406A PE20070806A1 (es) 2005-11-10 2006-11-09 Composicion farmaceutica que comprende un derivado de diarilurea

Country Status (18)

Country Link
US (1) US20100035888A1 (enExample)
EP (1) EP1948170A1 (enExample)
JP (1) JP5084736B2 (enExample)
KR (1) KR20080067000A (enExample)
AR (1) AR057849A1 (enExample)
AU (1) AU2006312714A1 (enExample)
BR (1) BRPI0618522A2 (enExample)
CA (1) CA2628849A1 (enExample)
CR (1) CR9953A (enExample)
EC (1) ECSP088430A (enExample)
GT (1) GT200800058A (enExample)
IL (1) IL191178A0 (enExample)
NO (1) NO20082498L (enExample)
PE (1) PE20070806A1 (enExample)
SV (1) SV2009002900A (enExample)
TW (1) TW200733961A (enExample)
UY (1) UY29903A1 (enExample)
WO (1) WO2007054216A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298311B1 (en) * 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
US7874293B2 (en) * 2003-02-21 2011-01-25 Resmed Limited Nasal assembly
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
AU2005289100B2 (en) * 2004-09-29 2011-11-03 Bayer Healthcare Llc Thermodynamically stable form of bay 43-9006 tosylate
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
ES2429107T3 (es) * 2007-01-19 2013-11-13 Bayer Healthcare Llc Tratamiento de cánceres con una resistencia adquirida a los agentes inhibidores de KIT
WO2009156070A1 (en) * 2008-06-25 2009-12-30 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
CN103079567A (zh) * 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
JP2013538840A (ja) 2010-10-01 2013-10-17 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 置換ｎ−（２−アリールアミノ）アリールスルホンアミドを含有する組み合わせ
EP2686429A4 (en) * 2011-03-14 2014-08-27 Cellworks Res India Private Ltd COMPOSITIONS, PROCESS FOR PREPARING THESE COMPOSITIONS AND METHOD FOR TREATING INFLAMMATORY DISEASES
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
WO2003084543A1 (en) * 2002-04-10 2003-10-16 Virginia Commonwealth University Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
EP1636585B2 (en) * 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl ureas with kinase inhibiting activity
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier

Also Published As

Publication number Publication date
CR9953A (es) 2008-10-08
GT200800058A (es) 2010-02-23
BRPI0618522A2 (pt) 2011-09-06
SV2009002900A (es) 2009-04-28
AR057849A1 (es) 2007-12-19
JP2009514910A (ja) 2009-04-09
NO20082498L (no) 2008-08-07
ECSP088430A (es) 2008-07-30
AU2006312714A1 (en) 2007-05-18
IL191178A0 (en) 2009-08-03
WO2007054216A1 (en) 2007-05-18
KR20080067000A (ko) 2008-07-17
US20100035888A1 (en) 2010-02-11
JP5084736B2 (ja) 2012-11-28
UY29903A1 (es) 2007-06-29
TW200733961A (en) 2007-09-16
CA2628849A1 (en) 2007-05-18
EP1948170A1 (en) 2008-07-30

Similar Documents

Publication Publication Date Title
DOP2006000210A (es) Compuestos de pirimidina amida como inhibidores de pgds
AR112074A2 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
SV2009002900A (es) Diarilurea para el tratamiento de hipertension pulmonar
CL2007000789A1 (es) Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
PA8511301A1 (es) Carboxiamidas de pirimidina utiles como inhibidores de isozimas pde4
CL2008002478A1 (es) Compuestos derivados de n-fenil-5-(4 haloalcoxi)fenil) pirimidin-2-amino, inhibidores de c-kit y pdgfr; composicion farmaceutica; y su uso en el tratmiento de asma, dermatitis atopica, hipertension pulmonar o arterial, fibrosis renal, pulmonar o cardiaca, entre otras.
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
CL2008000422A1 (es) El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
CL2012001221A1 (es) Compuestos derivados de 4 -(1h-pirrol-1-il) pirimidin -2-ilamino y 4 -(1h-pirazol-1-il)- pirimidin-2-ilamino, inhibidores de quinasa; un compuesto isomerico; composicion farmaceutica; utiles en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, colitis ulcerante, enfermedad de crohn, bronquitis, dermatitis, entre otras.
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
UY29575A1 (es) Formas polimórficas del éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino--imino-metil)-fenilamino)-metil)-1-metil-h-bencimidazol-5-carbonil)-piridin-2-il- -amino)-propiónico
NO20070445L (no) Pyrimidinderivater.
AR068369A1 (es) Sal de xinafoato de n4-[(2,2-difluor-4h-benzo[1,4]oxazin-3-on)-6-il]-5-fluor-n2-[3-(metilaminocarbonilmetilenoxi)-fenil]2,4-pirimidindiamina"
PE20120626A1 (es) Composiciones farmaceuticas que comprende nilotinib
PE20120516A1 (es) Inhibidor de la map cinasa p38
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
NO20083027L (no) Kontrollert frigivelses-fastformpreparat
PE20070362A1 (es) COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.

Legal Events

Date Code Title Description
FC Refusal